Cethromycin-Mediated Protection against the Plague Pathogen Yersinia pestis in a Rat Model of Infection and Comparison with Levofloxacin

Comparative Efficacies of Candidate Antibiotics against Yersinia pestis in an In Vitro Pharmacodynamic Model

(2011) Arnold Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Progress on plague vaccine development

(2011) Jason A. Rosenzweig et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Characterization of an F1 Deletion Mutant of Yersinia pestis CO92, Pathogenic Role of F1 Antigen in Bubonic and Pneumonic Plague, and Evaluation of Sensitivity and Specificity of F1 Antigen Capture-Based Dipsticks

(2011) J. Sha et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Use of anInVitroPharmacodynamic Model To Derive a Moxifloxacin Regimen That Optimizes Kill ofYersinia pestisand Prevents Emergence of Resistance

(2010) A. Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Milestones in Progression of Primary Pneumonic Plague in Cynomolgus Macaques

(2010) F. Koster et al.   INFECTION AND IMMUNITY

In vitro activity of cethromycin against Burkholderia pseudomallei and investigation of mechanism of resistance

(2010) T. Mima et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Cethromycin: A Promising New Ketolide Antibiotic for Respiratory Infections

(2010) Sally Rafie et al.   PHARMACOTHERAPY

Prevention of bubonic and pneumonic plague using plant-derived vaccines

(2009) M. Lucrecia Alvarez et al.   BIOTECHNOLOGY ADVANCES

Braun Lipoprotein (Lpp) Contributes to Virulence of Yersiniae: Potential Role of Lpp in Inducing Bubonic and Pneumonic Plague

(2008) J. Sha et al.   INFECTION AND IMMUNITY

Characterization of the rat pneumonic plague model: infection kinetics following aerosolization of Yersinia pestis CO92

(2008) Stacy L. Agar et al.   MICROBES AND INFECTION